Xceleron’s clinical research services help pharmaceutical and biotechnology clients to accelerate the drug development process and de-risk later clinical trial phases.
Clinical research teams turn to us to help them choose the best drug candidates before entering the clinical stages of pharmaceutical development, as well as to complete their regulatory submissions cost effectively and to problem-solve pharmacokinetic issues throughout the drug development process.
Using the enabling technology of accelerator mass spectrometry (AMS), Xceleron can detect and quantitate tiny traces of 14C-labeled drug, allowing for innovative clinical designs and analytical solutions unlike any other approach.
[pullquote]“The debate is over: AMS provides the route to better drug development paradigms / protocols.”
Dennis A. Smith, Pfizer Worldwide Research & Development[/pullquote]
The cost and drug development timeline savings from our approach can be considerable. Drug researchers can save up to one year in clinical development time by using our AMS approach for a mass balance/ADME study, for example.
Microdosing studies: a consideration on analytical technology choice
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.